全球膀胱癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球膀胱癌治療市場預計將從2025年的62.9億美元成長至2034年的192億美元，2026年至2034年的複合年成長率（CAGR）為13.2%。該市場的成長主要歸因於膀胱癌在全球範圍內日益嚴重的負擔以及治療方案的不斷發展。雖然傳統的膀胱癌治療主要依賴手術、化療、放射線治療和免疫療法，但分子標靶療法和新型治療方法的出現正在拓寬可用的治療策略範圍。公眾意識的提高、診斷技術的進步以及高風險族群篩檢的增加，都推動了疾病的早期發現。對分子特徵和疾病進展的持續研究，正在促進更具個人化療法的開發。製藥公司也在增加對癌症治療研發管線的投資，以滿足早期和晚期膀胱癌患者尚未滿足的醫療需求。

推動癌症治療需求成長的主要因素之一是免疫療法和標靶治療在晚期或復發性癌症患者中的應用日益廣泛。生物標記的研究正在幫助臨床醫生識別可能受益於特定治療的患者。聯合治療策略也在評估中，旨在提高治療效果並延長患者存活期。除了人口老化導致的癌症發生率上升外，吸菸等既定風險因素也進一步推高了治療需求。新興國家醫療基礎設施的改善和癌症治療的可近性有望為製藥公司帶來更多商機。

未來成長可能主要受精準腫瘤學、抗體藥物複合體（ADC）、聯合治療免疫療法和分子標靶療法等領域進展的影響。研發人員致力於提高療效，同時降低治療相關毒性並克服抗藥性。隨著治療選擇越來越主導生物標記，伴隨診斷的重要性可能會增加。發展中地區獲得先進癌症治療的機會改善也可能對市場產生正面影響。儘管監管要求和高昂的治療費用可能構成挑戰，但持續創新和強大的新型療法研發管線有望支持膀胱癌治療的長期發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球膀胱癌治療市場：依藥物分類

• 市場分析、洞察與預測
• Pembrolizumab
• 恩福坦布維多汀
• Avelumab
• Nivolumab
• 厄達替尼
• 納德法拉根·菲拉德諾維克
• 諾加潘德金α-invacicept
• 其他

第5章 全球膀胱癌治療市場：依產品類型分類

• 市場分析、洞察與預測
• 細胞毒性化學療法
• 免疫查核點抑制劑
• 抗體藥物複合體
• FGFR抑制劑
• 膀胱內免疫療法
• 基因療法/病毒載體療法
• 其他

第6章 全球膀胱癌治療市場：依疾病階段分類

• 市場分析、洞察與預測
• 非肌肉層浸潤性膀胱癌
• 肌肉層浸潤性膀胱癌
• 局部進行性/無法切除的膀胱癌
• 轉移性膀胱癌
• 其他

第7章 全球膀胱癌治療市場：依年齡層別分類

• 市場分析、洞察與預測
• 兒童
• 成人

第8章 全球膀胱癌治療市場：按類型分類

• 市場分析、洞察與預測
• 品牌
• 非專利的

第9章 全球膀胱癌治療市場：依療法分類

• 市場分析、洞察與預測
• 標靶治療
• 免疫療法
• 化療
• 其他

第10章 全球膀胱癌治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外
• 膀胱內給藥

第11章 全球膀胱癌治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 藥局和零售藥房
• 網路藥房
• 專科藥房

第12章 全球膀胱癌治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第13章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第14章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck & Co. Inc
  • Astellas Pharma Inc
  • Bristol Myers Squibb Company
  • Pfizer Inc
  • Johnson & Johnson
  • Ferring Pharmaceuticals
  • ImmunityBio Inc
  • AstraZeneca Plc
  • UroGen Pharma Inc
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Eli Lilly And Company
  • Novartis AG
  • Amgen Inc
  • Sanofi SA
  • GSK Plc
  • BeiGene Ltd
  • Exelixis Inc

The global bladder cancer therapeutics market size is expected to reach USD 19.20 Billion in 2034 from USD 6.29 Billion in 2025, growing at a CAGR of 13.2% during 2026-2034.This market is expanding as the global burden of bladder cancer increases and treatment options continue to evolve. Bladder cancer management traditionally relies on surgery, chemotherapy, radiation, and immunotherapy, while targeted and newer therapeutic approaches are expanding available treatment strategies. Rising awareness, improvements in diagnostic technologies, and increasing screening among high-risk populations are supporting earlier disease identification. Continued research into molecular characteristics and disease progression is enabling the development of more personalized treatments. Pharmaceutical companies are also increasing investment in oncology pipelines to address unmet needs across early-stage and advanced bladder cancer.

One of the major drivers is the growing adoption of immunotherapy and targeted treatments for patients with advanced or recurrent disease. Research into biomarkers is helping clinicians identify patients who may benefit from specific therapies. Combination treatment strategies are also being evaluated to improve treatment responses and extend survival. Increasing incidence among aging populations, along with established risk factors such as tobacco exposure, further contributes to demand for therapeutics. Improvements in healthcare infrastructure and oncology treatment access in emerging economies are expected to provide additional opportunities for pharmaceutical manufacturers.

Future growth is likely to be shaped by advances in precision oncology, antibody-drug conjugates, immunotherapy combinations, and molecularly targeted medicines. Developers are focusing on improving efficacy while reducing treatment-related toxicity and overcoming resistance. Companion diagnostics may become increasingly important as treatment selection becomes more biomarker-driven. The market could also benefit from improved access to advanced cancer therapies in developing regions. Although regulatory requirements and high treatment costs may create challenges, continued innovation and a strong pipeline of novel therapies are expected to support the long-term development of bladder cancer therapeutics.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Pembrolizumab
• Enfortumab Vedotin
• Avelumab
• Nivolumab
• Erdafitinib
• Nadofaragene Firadenovec
• Nogapendekin Alfa Inbakicept
• Others

By Product Type

• Cytotoxic Chemotherapy
• Immune Checkpoint Inhibitors
• Antibody-Drug Conjugates
• FGFR Inhibitors
• Intravesical Immunotherapy
• Gene Therapy/Viral Vector Therapy
• Others

By Disease Stage

• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer
• Locally Advanced/Unresectable Bladder Cancer
• Metastatic Bladder Cancer
• Others

By Age Group

• Pediatric
• Adults

By Type

• Branded
• Generic

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

By Route of Administration

• Oral
• Parenteral
• Intravesical

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

COMPANIES PROFILED

• Merck & Co. Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Pfizer Inc., Johnson & Johnson, Ferring Pharmaceuticals, ImmunityBio Inc., AstraZeneca plc, UroGen Pharma Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Eli Lilly and Company, Novartis AG, Amgen Inc., Sanofi S.A., GSK plc, BeiGene Ltd., Exelixis Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Pembrolizumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Enfortumab Vedotin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Avelumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nivolumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Erdafitinib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Nadofaragene Firadenovec Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Nogapendekin Alfa Inbakicept Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Cytotoxic Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immune Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Antibody-Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. FGFR Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Intravesical Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Gene Therapy/Viral Vector Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DISEASE STAGE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Stage
• 6.2. Non-Muscle-Invasive Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Muscle-Invasive Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Locally Advanced/Unresectable Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metastatic Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Type
• 8.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY THERAPY 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Therapy
• 9.2. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Route Of Administration
• 10.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Intravesical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast Distribution Channel
• 11.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 12.1. Regional Outlook
• 12.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.2.1 By Drug
  • 12.2.2 By Product Type
  • 12.2.3 By Disease Stage
  • 12.2.4 By Age Group
  • 12.2.5 By Type
  • 12.2.6 By Therapy
  • 12.2.7 By Route Of Administration
  • 12.2.8 By Distribution Channel
  • 12.2.9 United States
  • 12.2.10 Canada
  • 12.2.11 Mexico
• 12.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.3.1 By Drug
  • 12.3.2 By Product Type
  • 12.3.3 By Disease Stage
  • 12.3.4 By Age Group
  • 12.3.5 By Type
  • 12.3.6 By Therapy
  • 12.3.7 By Route Of Administration
  • 12.3.8 By Distribution Channel
  • 12.3.9 United Kingdom
  • 12.3.10 France
  • 12.3.11 Germany
  • 12.3.12 Italy
  • 12.3.13 Russia
  • 12.3.14 Rest Of Europe
• 12.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.4.1 By Drug
  • 12.4.2 By Product Type
  • 12.4.3 By Disease Stage
  • 12.4.4 By Age Group
  • 12.4.5 By Type
  • 12.4.6 By Therapy
  • 12.4.7 By Route Of Administration
  • 12.4.8 By Distribution Channel
  • 12.4.9 India
  • 12.4.10 Japan
  • 12.4.11 South Korea
  • 12.4.12 Australia
  • 12.4.13 South East Asia
  • 12.4.14 Rest Of Asia Pacific
• 12.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.5.1 By Drug
  • 12.5.2 By Product Type
  • 12.5.3 By Disease Stage
  • 12.5.4 By Age Group
  • 12.5.5 By Type
  • 12.5.6 By Therapy
  • 12.5.7 By Route Of Administration
  • 12.5.8 By Distribution Channel
  • 12.5.9 Brazil
  • 12.5.10 Argentina
  • 12.5.11 Peru
  • 12.5.12 Chile
  • 12.5.13 Rest of Latin America
• 12.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.6.1 By Drug
  • 12.6.2 By Product Type
  • 12.6.3 By Disease Stage
  • 12.6.4 By Age Group
  • 12.6.5 By Type
  • 12.6.6 By Therapy
  • 12.6.7 By Route Of Administration
  • 12.6.8 By Distribution Channel
  • 12.6.9 Saudi Arabia
  • 12.6.10 UAE
  • 12.6.11 Israel
  • 12.6.12 South Africa
  • 12.6.13 Rest of the Middle East And Africa

Chapter 13. COMPETITIVE LANDSCAPE

• 13.1. Recent Developments
• 13.2. Company Categorization
• 13.3. Supply Chain & Channel Partners (based on availability)
• 13.4. Market Share & Positioning Analysis (based on availability)
• 13.5. Vendor Landscape (based on availability)
• 13.6. Strategy Mapping

Chapter 14. COMPANY PROFILES OF GLOBAL BLADDER CANCER THERAPEUTICS INDUSTRY

• 14.1. Top Companies Market Share Analysis
• 14.2. Company Profiles
  • 14.2.1 Merck & Co. Inc
  • 14.2.2 Astellas Pharma Inc
  • 14.2.3 Bristol Myers Squibb Company
  • 14.2.4 Pfizer Inc
  • 14.2.5 Johnson & Johnson
  • 14.2.6 Ferring Pharmaceuticals
  • 14.2.7 ImmunityBio Inc
  • 14.2.8 AstraZeneca Plc
  • 14.2.9 UroGen Pharma Inc
  • 14.2.10 F. Hoffmann-La Roche Ltd
  • 14.2.11 Merck KGaA
  • 14.2.12 Eli Lilly And Company
  • 14.2.13 Novartis AG
  • 14.2.14 Amgen Inc
  • 14.2.15 Sanofi S.A
  • 14.2.16 GSK Plc
  • 14.2.17 BeiGene Ltd
  • 14.2.18 Exelixis Inc